Both Axonics Modulation Technologies Inc. (NASDAQ:AXNX) and ReShape Lifesciences Inc. (OTCMKTS:RSLS) are Medical Appliances & Equipment companies, competing one another. We will contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Axonics Modulation Technologies Inc.||N/A||1140.81||32.48M||-1.10||0.00|
|ReShape Lifesciences Inc.||2.75M||0.28||67.08M||-876.51||0.00|
Table 1 highlights Axonics Modulation Technologies Inc. and ReShape Lifesciences Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 has Axonics Modulation Technologies Inc. and ReShape Lifesciences Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axonics Modulation Technologies Inc.||0.00%||0%||0%|
|ReShape Lifesciences Inc.||-2,439.27%||0%||0%|
Institutional and Insider Ownership
Roughly 78.2% of Axonics Modulation Technologies Inc. shares are held by institutional investors while 2.42% of ReShape Lifesciences Inc. are owned by institutional investors. About 4% of Axonics Modulation Technologies Inc.’s share are held by insiders. Competitively, 0.02% are ReShape Lifesciences Inc.’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Axonics Modulation Technologies Inc.||-0.05%||46.85%||52.16%||0%||0%||41.89%|
|ReShape Lifesciences Inc.||8.82%||29.82%||-55.69%||-96.15%||-99.99%||45.1%|
For the past year Axonics Modulation Technologies Inc. has weaker performance than ReShape Lifesciences Inc.
Axonics Modulation Technologies Inc. beats on 5 of the 7 factors ReShape Lifesciences Inc.
EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company develops the vBloc System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.